With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA – Scrip

Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% …